Fluoroquinolone Toxicity Study

Call Directions Website Contact the organization

Fluoroquinolone Toxicity Study With these study conclusions, evaluation of preventative and restorative treatment will be explored.

Fluoroquinolone Toxicity Study is a nonprofit 501(c)(3) organization dedicated to driving collaborative research at the cellular & molecular level, aimed to identify the mechanism of damage that can be induced by the fluoroquinolone class of antibiotics. Our mission is to perform research at the cellular and molecular level in collaboration with scientists to determine the mechanism of damage caused by Fluoroquinolones.

10/08/2026

🎥 It was the quinolones – new documentary in the works, check it out/become a participant!

Hélène Mastrodicasa, fellow floxie, has asked the Foundation to share her documentary project regarding fluoroquinolone antibiotics adverse effects and which “explores paths of resilience, potential solutions and possible institutional levers.”

She is seeking additional international participants to share a brief testimony of their experience (contact below) and any size donation you can spare to get this movie up onto screens (link below).

🎥 “This documentary was born out of a deep conviction: the importance of informing the general public, with honesty, kindness, and scientific rigor, about the often unknown risks associated with certain treatments, particularly fluoroquinolones.”

🎯To help fund this project and learn more about this:
https://whydonate.com/fundraising/documentary-it-was-the-quinolones

➥ If you would like to participate - contact Helene via direct message on Facebook: https://www.facebook.com/profile.php?id=720844133 or [email protected]

A teaser highlight :
https://www.facebook.com/reel/1509640264526923

Talia Smith Lin Stevs Eric Elliott Andrew R Pravata

10/03/2026

💠Stem Cells, Mitochondrial “Transplants,” and What Our Poland iPSC Work Suggests for FQAD (Part 3 Final)

When people hear “stem cells” or “mitochondrial transplantation,” it is easy to imagine a near-future medicine where damaged tissues simply receive fresh cellular “batteries” and everything switches back on.
The reality is more demanding:

➦the science is advancing quickly, but the biology is complex, the manufacturing is unforgiving, and patient-to-patient variability, especially in syndromes involving mitochondrial injury and extreme sensitivity, can make promising concepts behave unpredictably.

One of the most important reasons to stay realistic comes from our research work done in Poland in 2022, published in the journal Stem Cell Research & Therapy. This work examined whether fibroblasts from people with Fluoroquinolone-Associated Disability (FQAD) could be reprogrammed into induced pluripotent stem cells (iPSCs) and then expanded reliably. The central finding was uncomfortable but crucial: compared with healthy controls, reprogramming and stable line establishment were markedly harder in FQAD, with many patient samples failing to produce robust iPSC lines and showing signs consistent with impaired regenerative capacity under standard conditions. The paper’s message is not “give up,” but rather “do not assume autologous iPSC-based therapies will behave like they do in healthy donors; the manufacturing bottlenecks may reflect true biology.” That is exactly the kind of reality check that should shape next steps, including how we design cell-line models, what we consider “success” in culture, and how we interpret poor growth as data rather than “bad luck.” [1]

At the same time, regenerative medicine is not a single road. If iPSC routes can be blocked by the patient’s cellular state, the field increasingly looks at parallel strategies: mesenchymal stromal/stem cells (MSCs), cell-free products (secretome, extracellular vesicles), and, more experimentally, direct mitochondrial delivery. The reason mitochondria are at the center of this discussion is simple: mitochondria are not only energy producers; they are metabolic control hubs, immune-signaling hubs, and stress sensors. In conditions where mitochondria are damaged, the downstream effects can spread to detox pathways, redox balance, connective tissue remodeling, and neuro-immune stability, precisely the systems many FQAD patients report as fragile.

So how would mitochondria get from a donor source to a recipient cell in a way that could matter?

Nature already has a few “transport channels,” and researchers have been mapping them. One highly studied route is the formation of tunneling nanotubes (TNTs), thin actin-based bridges that can connect cells and allow organelle transfer. Work in different tissues has shown that TNT formation depends on specific proteins and stress signaling, and the system is not random. For example, TNFAIP2 (also called M-Sec) has been tied to TNT formation, and TNTs have been implicated as conduits for organelle movement in multiple models. [2] This matters because it reframes “mitochondrial transfer” from something mystical into something that can be engineered: if cells build highways under stress, the practical question becomes how to promote safe, controlled highway formation without triggering unwanted inflammation.

A second key concept is that mitochondrial movement is not just about having mitochondria available; it is about trafficking machinery. Several studies point to the mitochondrial Rho-GTPase Miro1 as a major regulator of mitochondrial transport. In the lung/airway context, Miro1 was shown to regulate intercellular mitochondrial movement from MSCs to epithelial cells, and increasing Miro1 expression in MSCs increased mitochondrial transfer and improved rescue effects in animal models. [3] In neural models, Miro1-enhanced MSCs transferred mitochondria more effectively and were associated with improved functional recovery after experimental injury. [4] In plain language: there are “biological transport knobs” that can change how effectively mitochondria are mobilized and delivered.

A third route is packaging: mitochondria (or mitochondrial components and mitochondrial-regulating molecules) can be moved inside extracellular vesicles/microvesicles or related membrane structures. This is often described as “horizontal transfer” of mitochondrial material and signals, and it is one reason cell-free therapies remain attractive: they may carry some regenerative signaling while avoiding the full complexity and risk profile of transplanting living, dividing cells. A recent review in Stem Cells discusses how extracellular vesicles/exosomes can participate in transfer of mitochondria and mitochondria-related regulatory molecules, framing them as potential “delivery vehicles” while still emphasizing open mechanistic questions. [5]

Then there is the idea that many patients find most intuitive: isolating mitochondria and administering them directly, hoping they will “go where they are needed.” Here, the field splits into hopeful data and serious skepticism. On the hopeful side, an International Journal of Molecular Sciences study reported that exogenous mitochondria showed preferential trafficking toward cells and tissues with mitochondrial damage in vitro and in vivo, supporting the idea that injury states can create “signals” that bias uptake. [6] On the skepticism side, a Journal of Clinical Investigation viewpoint laid out why extraordinary claims require extraordinary evidence, discussing basic barriers: survival of mitochondria in high extracellular calcium, immune clearance, endothelial barriers, actual entry into target cells, and whether enough mitochondria enter to meaningfully shift ATP production. [7] Both perspectives are valuable: the first motivates exploration; the second prevents the field from turning into marketing.

Because biology is only half the battle, the other half is production. If a therapy depends on MSCs, vesicles, or even standardized mitochondrial preparations, you need reproducible culture at meaningful scale. That is where advanced perfusion bioreactors and hollow-fiber systems enter the story: they are designed to sustain high-density cultures with controlled media exchange and stable conditions, often as a bridge between benchtop research and consistent manufacturing. Systems such as the AcuSyst-Xcellerator are marketed as flexible production-scale bioreactors for mammalian cell culture and related workflows, reflecting the broader industry shift toward controlled, scalable cell manufacturing rather than artisanal flask work. [8] Whether one calls this “the California accelerator” or simply the modern manufacturing layer, the point is the same: if regenerative medicine is to become real medicine, it must be reproducible, scalable, and quality-controlled.

➦For FQAD patients specifically, the most responsible message is “measured hope.” The hope is that mitochondrial delivery, via cells, nanotubes, vesicles, or engineered carriers, could one day help restore function in tissues where mitochondria are chronically impaired. The non-negotiable caution is that FQAD biology may make standard assumptions fail. If patient-derived cells reprogram poorly or expand unreliably, as shown in the iPSC work, then autologous “take your cells, fix them, give them back” models can run into real-world barriers before therapy even begins. [1] In addition, any intervention that moves mitochondria or mitochondrial material between cells risks immune activation, because mitochondria can behave like danger signals when they are damaged or released in the wrong context. And iPSC-derived therapies carry their own high-stakes risks, genomic instability, abnormal differentiation, tumorigenicity - requiring stringent QC and conservative clinical translation.

💠This is why our research direction, grounded in careful mechanistic work, controlled models, and rigorous analytics, matters. If we want the future to be more than stories, we must build it from data: defining which signals are present in FQAD cells, what breaks during reprogramming and proliferation, how mitochondrial damage shapes trafficking and uptake, and which delivery routes can be made safe, targeted, and reproducible. It is not a “pink and beautiful” road, but a technical road. But it is a road that exists and it is getting wider.

🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿🧿
✏️Disclaimer: This article is for general educational discussion and research-context planning only. It is not medical advice, does not establish a diagnosis or treatment recommendation, and should not be used to make clinical decisions without qualified medical oversight and appropriate regulatory-grade evidence.

💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: https://fq100.org/drug-list

Find support and resources on our sites:

🌐 Find Us: https://fq100.org/
▶️ YouTube: https://www.youtube.com/
🔵 Facebook: https://www.facebook.com/fqtoxicitystudy/
🐦 X/Twitter: https://twitter.com/FQ_100

References:
[1] Grot D, et al. Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy. Stem Cell Research & Therapy (2022). (PubMed)
[2] Barutta F, et al. Protective Role of the M-Sec, Tunneling Nanotube System in Podocytes. Journal of the American Society of Nephrology (2021). (PubMed)
[3] Ahmad T, et al. Miro1 regulates intercellular mitochondrial transport, enhances mesenchymal stem cell rescue efficacy. The EMBO Journal (2014). (PubMed)
[4] Babenko VA, et al. Miro1 Enhances Mitochondria Transfer from Multipotent Mesenchymal Stem Cells (MMSC) to Neural Cells and Improves the Efficacy of Cell Recovery. Molecules (2018). (PubMed)
[5] Ratajczak MZ, et al. Extracellular microvesicles/exosomes, magic bullets in horizontal transfer between cells of mitochondria and molecules regulating mitochondria activity. Stem Cells (2025). (PubMed)
[6] Lee S-E, et al. Preferred Migration of Mitochondria toward Cells and Tissues with Mitochondrial Damage. International Journal of Molecular Sciences (2022). (PubMed)
[7] Bertero E, Maack C, O’Rourke B. Mitochondrial transplantation in humans, “magical” cure or cause for concern? Journal of Clinical Investigation (2018). (PubMed)
[8] Cell Culture Company. AcuSyst-Xcellerator, Flexible Production Scale Bioreactor (product page). (Hollow Fiber)

✨An important step forward for our FQAD community✨We recently traveled to meet with Dr. Peter McCullough to discuss fluo...
09/25/2026

✨An important step forward for our FQAD community✨

We recently traveled to meet with Dr. Peter McCullough to discuss fluoroquinolone* toxicity, the daily reality of living with its effects, and the research our Foundation, Fluoroquinolone Toxicity Study NFP, is working to advance. Our fellow Foundation partner, Jane, was unfortunately unable to join us in person.

Despite his extremely demanding schedule, including his ongoing work on COVID-19, Dr. McCullough made time to listen and indicated that there may be an opportunity to collaborate with our Foundation. He also introduced us to a specialty laboratory that will be examining the data we provided. This is an encouraging first step toward the scientific attention our community has sought for years. We sincerely appreciate his time and openness. We also admire his courage in asking difficult questions, challenging established positions, and speaking publicly about issues he believes deserve scrutiny. His willingness to hear our concerns means a great deal to people who have struggled for years to have their experiences taken seriously.

We provided our most important research materials and documentation to help Dr. McCullough, his foundation’s team, and the scientists reviewing our work understand the scope of the problem. FQAD remains unfamiliar to many people outside our community, including most physicians. Its complexity requires careful examination, and reviewing these materials and considering the next steps will take time. Our conversation also included newer approaches to RNA expression analysis and the possibility of exploring individualized treatment strategies involving mitochondrial function and metabolic pathways. We want to work with scientists and laboratories to investigate whether these approaches could help explain persistent injury and eventually guide treatment. Their usefulness in FQAD still needs to be established, but these are meaningful questions worth pursuing.

Much of our Foundation’s work happens behind the scenes. Conversations, scientific preparation, and research planning cannot always be shared while they are still developing. We continue this work while living with the physical and cognitive challenges of FQAD ourselves. We know what it means to wait for answers because we are waiting for them, too. Sometimes the best laid plans fall apart and barriers can’t be overcome.
Our goal remains clear:
advance rigorous research, develop objective diagnostic methods, and help build a path toward effective treatment. This work cannot happen overnight, but we are determined to develop the opportunities this meeting has opened.

✨ Now we need your voices.

➦ Please share a brief account of your experience in the comments below, wherever you live in the world.
Tell us which fluoroquinolone you took, how long you have been affected, and how your life changed. What happened to your health, your work, your family life, or your independence? What do you most want physicians and researchers to understand?
Your stories can help Dr. McCullough and his foundation see the human reality behind the research: the years of illness, the lost opportunities, and the determination of people still searching for help. They can also make the international reach of this problem more visible. Every account represents a person whose suffering deserves attention.

Since the Foundation began, we have worked without pay and personally covered all travel expenses as well as most administrative and research expense. We give our time and resources because this mission matters deeply to us. If you would like to help us continue, donations of any size to support the Foundation’s research and outreach are welcome via our Contact Us page:
https://fq100.org/contact-us
✨ Your support helps us pursue the scientific collaborations and investigations our community needs✨

Thank you, Dr. McCullough, for considering how you might help move this research forward. Thank you to everyone who supports us, shares their experience, and continues to stand with our community. There is substantial work ahead, and we remain determined to carry it forward.

On behalf of the Board of Directors
Fluoroquinolone Toxicity Study NFP
Jerzy Tyszkowski
Jane Crosby
Sarah Sedgwick

*💊The main systemic fluoroquinolones used in the United States today include levofloxacin (Levaquin - discontinued), ciprofloxacin (Cipro), moxifloxacin (Avelox - discontinued), ofloxacin (Floxin), gemifloxacin (Factive), and delafloxacin (Baxdela). Most listed brand names are now discontinued except Cipro and Baxdela. See complete list in all forms for humans and pets: https://fq100.org/drug-list

Find support and resources on our sites:

🌐 Website & Resources: https://fq100.org/
▶️ YouTube: https://www.youtube.com/
🔵 Facebook: https://www.facebook.com/fqtoxicitystudy/
🐦 X: https://x.com/FQ_100

Peter A McCullough, MD, MPH Robert F. Kennedy, Jr

Your next doctor visit is a chance to make sure your adverse effects from fluoroquinolone* antibiotics are documented!We...
09/23/2026

Your next doctor visit is a chance to make sure your adverse effects from fluoroquinolone* antibiotics are documented!

We’ve put together resources to help you walk in prepared: an adverse effects checklist form, materials for your doctor, and information about the fluoroquinolone diagnosis code. You don’t have to explain everything from memory.

Take a look before your next appointment, and share this with someone who could use it:

https://fq100.org/find-help

* 💊The main systemic fluoroquinolones used in the United States today include levofloxacin (Levaquin - discontinued), ciprofloxacin (Cipro), moxifloxacin (Avelox - discontinued), ofloxacin (Floxin), gemifloxacin (Factive), and delafloxacin (Baxdela). Most listed brand names are now discontinued except Cipro and Baxdela. See complete list in all forms for humans and pets: https://fq100.org/drug-list

Find support and resources on our sites:

🌐 Website & Resources: https://fq100.org/
▶️ YouTube: https://www.youtube.com/
🔵 Facebook: https://www.facebook.com/fqtoxicitystudy/
🐦 X: https://x.com/FQ_100

Help Lauren Support FQ Advocacy!Lauren, a former high school teacher living with disabling fluoroquinolone adverse effec...
09/11/2026

Help Lauren Support FQ Advocacy!

Lauren, a former high school teacher living with disabling fluoroquinolone adverse effects, is working to bring this issue to the attention of the N. Carolina Attorney General. She is requesting a meeting with the Attorney General’s office and would be accompanied by Dr. Charles Bennett** to discuss the serious, lasting consequences and inadequate warnings, starting in her State.

Personal stories can help demonstrate that these experiences are NOT isolated. If you would like to support Lauren’s efforts, particularly if you live in North Carolina, please consider submitting a short written account of what happened to you.

✅Lauren has asked that you emphasize that the patient literature did not accurately reflect the scope of your adverse reactions

Your story could also include:

✅The adverse effects you are experiencing and for how long
✅How your health, employment, finances or family life have been affected
✅Whether you were warned about the possibility of disabling or potentially irreversible adverse effects
✅Any difficulty you experienced obtaining medical recognition, documentation, treatment or disability benefits

Even a few paragraphs can help put a human face on this issue. Each personal account adds to a clearer picture of how fluoroquinolone adverse effects can affect individuals, families and the broader healthcare and disability systems.

➥➥ Please send your story to Attorney General Jackson: [email protected]

✨✨Thank you for helping Lauren ensure that the experiences of this community are heard and taken seriously✨✨

** Dr. Bennett - is a hematologist, oncologist and professor in the Department of Clinical Pharmacy and Outcomes Sciences at the University of South Carolina College of Pharmacy. His career has focused on identifying, investigating and helping prevent serious adverse drug events. He founded the Research on Adverse Drug Events and Reports program and is affiliated with the Southern Network on Adverse Reactions, a pharmacovigilance network involving researchers from approximately 50 medical universities. He has significant knowledge on the issues surrounding FQ medications.

Fluoroquinolone antibiotics in infant formula, meat, eggs, water, soil, and honey – the silent circulation of a drugFluo...
09/08/2026

Fluoroquinolone antibiotics in infant formula, meat, eggs, water, soil, and honey – the silent circulation of a drug

Fluoroquinolones are modern, broad-spectrum antibiotics used on a massive scale in human and veterinary medicine. They save lives in acute infections, but they are also among the drugs most frequently associated with long-lasting adverse effects, including tendon damage, neuropathy, dysautonomia, and probable mitochondrial injury. For people who have already been harmed by fluoroquinolones, even tiny “background” exposures become a worrying question: are traces of these drugs still circulating in our food and environment, and if so, what could that mean for sensitive individuals?

Over the past 15–20 years, analytical chemistry has provided an uncomfortable answer. Thanks to sensitive methods such as solid-phase extraction, pressurized liquid extraction, and LC–MS/MS, researchers have shown that fluoroquinolone residues can be found in almost every part of the food chain: in infant and young-child milk powders, meat, eggs, fish, honey, drinking and aquaculture water, and even in agricultural soils and vegetables irrigated with contaminated water. These concentrations are usually low and, under current regulations, are considered safe for the general population. But they are not zero, and they are biologically active molecules designed to interact with DNA and mitochondria.

❓In the context of fluoroquinolone-associated disability (FQAD) and mitochondrial dysfunction, this raises a simple but profound question: what is the effect of chronic micro-dosing through food, water and environmental exposure in people whose detoxification and repair systems are already weakened❓

🧿 Fluoroquinolones in infant formula and baby foods

Infant formula and baby foods are some of the most strictly regulated products on the market. In the European Union, veterinary antimicrobials are not permitted in baby foods, so a “zero-tolerance” policy applies. In practice, this means that any detectable residue is considered illegal, even if the absolute amount is minimal.

Despite this, several independent groups – mainly in Spain and other European countries – have developed methods that detect fluoroquinolone residues in commercial baby foods and powdered infant formula. Rodríguez and co-workers validated a solid-phase extraction and LC–LC-fluorescence method for powdered infant formula from the Spanish and Latin-American market and showed that traces of fluoroquinolones can be measured at levels of a few μg/kg. Other work by the same team used pressurized liquid extraction combined with LC–FLD to analyse infant food products containing meat, chicken, and fish. In that study, a chicken-based baby food sample was found to be non-compliant because of enrofloxacin residues, confirmed by LC–MS/MS.

A further step was taken by Herrera-Herrera and colleagues, who applied SPE and UPLC–MS/MS to infant and young-child powdered milks and could simultaneously quantify multiple quinolones and fluoroquinolones (including levofloxacin, ciprofloxacin, enrofloxacin and moxifloxacin) at very low concentrations. These methods show that, technically, it is possible to detect and quantify fluoroquinolone residues in infant milks at low μg/kg levels, and that some marketed products do contain measurable residues, even where legislation assumes they should be absent.

Why do infant products contain any fluoroquinolones at all? The main explanation is upstream: dairy cows treated with veterinary fluoroquinolones may continue to excrete residues in milk if withdrawal times are not respected or if extra-label use occurs. Residues can also enter the milk supply through contaminated water, feed, and biofilms in pipelines. Reviews on veterinary drug residues in the food chain emphasise that inappropriate dosing, failure to observe withdrawal periods, and the use of antimicrobials as growth promoters have all contributed to a background level of antibiotic residues in milk and dairy products worldwide.
For healthy infants, regulators assume that the combination of low concentrations, short exposure, and safety factors keeps the risk minimal. But for families in which the mother has a history of fluoroquinolone toxicity or mitochondrial dysfunction, the idea that formula or baby foods may contain small amounts of the same class of drug is understandably alarming – especially in the context of clinical stories where children show joint noises, ligament problems or developmental symptoms despite never receiving the drug directly.

🧿 Meat, eggs, and fish – residues surviving cooking and freezing

Fluoroquinolones are widely used in poultry, pigs, cattle and aquaculture. Their residues are regularly detected in raw meat and edible tissues. Studies from Europe, Asia and Africa have reported ciprofloxacin, enrofloxacin, norfloxacin and other fluoroquinolones in chicken muscles, liver, and gizzards, sometimes above the maximum residue limits (MRLs) and sometimes below but still measurable.

Eggs are not exempt. A method using pressurized liquid extraction and LC–FLD was developed for enrofloxacin, ciprofloxacin and sarafloxacin in table eggs, demonstrating that residues can be reliably extracted from yolk and albumen and quantified at low μg/kg levels. This does not mean that every egg contains antibiotic residues, but it does confirm that fluoroquinolones can reach eggs when laying hens are treated improperly.

The next logical question is whether standard kitchen processing destroys these residues. For many antibiotics, heating and boiling do significantly reduce the concentration. For fluoroquinolones, the picture is more complicated. In a classic study, Lolo and colleagues examined naturally occurring enrofloxacin residues in chicken meat and tested boiling, microwaving, roasting, grilling, and frying. They found that enrofloxacin (and its active metabolite ciprofloxacin) were remarkably heat-stable: in some cooking modes the absolute concentration in the meat decreased modestly, but in others it even appeared to increase because water was lost. The residue became more concentrated in the remaining tissue.

Other experimental work confirms that boiling, microwaving and roasting usually lead to only partial reduction of fluoroquinolone residues, and part of the lost fraction simply migrates into the cooking water or juices, rather than being destroyed. From the point of view of a sensitive consumer, this means that grilled or roasted meat from recently treated animals can still contain biologically relevant amounts of fluoroquinolones after cooking and freezing. Long-term freezing does not reliably remove these residues; it mainly slows down microbial growth and enzymatic reactions, while the antibiotic molecule remains largely intact.

🧿 Honey and bees – fluoroquinolones in a “natural” product

Honey is often perceived as a clean, almost medicinal product. However, in modern beekeeping, it can be contaminated with antibiotics used to control bacterial infections in hives. Fluoroquinolones, including banned substances like norfloxacin, have been detected in honey samples from several countries.
Kanda and co-workers developed a microbiological screening test combined with liquid chromatography to rapidly determine seven fluoroquinolones (norfloxacin, ciprofloxacin, danofloxacin, enrofloxacin, orbifloxacin, sarafloxacin, and difloxacin) in honey. More recently, a five-year study in Zhejiang Province, China, analysed 681 honey samples from Apis mellifera and Apis cerana and found that four fluoroquinolones were detected in about 7% of samples. Norfloxacin – a drug banned in bee products – showed the highest detection frequency and reached concentrations as high as 7,890 μg/kg in some r**e honey samples.

A systematic review and meta-analysis of antibiotics in honey confirms that, globally, residues of various antimicrobial classes (including fluoroquinolones) are frequently found, with substantial variability between countries and production systems. Importantly, there are also many honey samples where no antibiotics are detected, especially from producers who do not use veterinary drugs in beekeeping. But from the perspective of someone with FQAD, the presence of even a small fraction of contaminated honey on the market is enough to justify caution and, where possible, choosing producers who provide independent residue testing.

🧿 Water, aquaculture and the aquatic environment

Fluoroquinolones are mainly excreted unchanged in urine and faeces, and they bind strongly to sediments and organic matter. Wastewater treatment plants only partially remove them. As a result, they have been detected in surface waters (rivers and lakes), aquaculture ponds, and even some drinking-water sources in various parts of the world.

A**lytical methods using molecularly imprinted solid-phase extraction and LC–MS/MS have shown that ultratrace concentrations (ng/L) of multiple fluoroquinolones can be present in drinking water and fish-farm water. In hotspots downstream of pharmaceutical manufacturing or large hospitals, levels can be orders of magnitude higher, creating a powerful selection pressure for resistant bacteria and a chronic low-dose exposure to humans and animals.

Fish raised in contaminated water can accumulate fluoroquinolones in their tissues, especially in organs like the liver and kidney, but also in edible muscle. Reviews of veterinary drug residues in aquaculture products consistently list ciprofloxacin, enrofloxacin, and related drugs as major contaminants of concern.

🧿 Soil, manure, and vegetables – antibiotics in the field

What is excreted by animals or discharged with effluents does not disappear. It ends up in manure, sludge, and agricultural soils. Several studies have documented fluoroquinolone residues in soils irrigated with wastewater or fertilized with contaminated manure, often at levels of tens to hundreds of μg/kg.

In an intensive vegetable-growing area in northern China, fluoroquinolone residues in soil were linked to planting patterns and to the use of contaminated irrigation water. Research from the Yamuna River region in India showed that spinach and other leafy vegetables irrigated with pharmaceutical-contaminated water accumulated antibiotics, with ofloxacin reaching measurable concentrations in edible leaves. This confirms that antibiotics can move from water to soil and then into plant tissues, entering the human diet even in products that do not contain veterinary drugs.
From a regulatory standpoint, these levels are still low and there are currently no specific maximum residue limits for fluoroquinolones in vegetables. From a mechanistic standpoint, they are another piece of the puzzle: a small but chronic dose of DNA-active, mitochondria-targeting molecules in the daily diet.
❓❓What does this mean for people with FQAD and mitochondrial dysfunction?
For the average consumer, risk assessments compare estimated daily exposure from food and water with an acceptable daily intake (ADI) derived from animal toxicology, multiplied by safety factors. Under this framework, most measured fluoroquinolone residues in food fall below the thresholds considered risky.
However, people with profound fluoroquinolone-associated injury do not fit the “average consumer” model. Many report hypersensitivity to tiny exposures, including eye or ear drops, traces in food, or dust from pharmacy pills. Mechanistically, this is not implausible. Fluoroquinolones are known to:

➤➤ Inhibit bacterial and mitochondrial topoisomerases and interfere with DNA replication and repair.

➤➤ Generate oxidative stress and damage mitochondrial membranes.

➤➤ Chelate magnesium and other cations essential for energy metabolism.

If mitochondria are already damaged and antioxidant reserves are exhausted, even minor additional hits may prolong inflammation, delay regeneration, and maintain a state of “cellular alarm”. For these patients, chronic, low-dose exposure through food and water could, in theory, act as a constant background stressor – something like a weak but persistent flame under a pot that never quite cools down.

At the same time, it is essential to be honest about the scientific evidence. We have solid data showing the presence of fluoroquinolone residues in infant formula, baby foods, meat, eggs, honey, water, soil and vegetables. What we do not yet have are large, controlled studies directly linking these background residues to clinical relapses or progression of FQAD. That research still needs to be done.

❓❓What, then, can a cautious but realistic approach look like?

1. Awareness. Knowing that fluoroquinolone residues can be present in animal-derived foods, honey, and some plant products helps patients and clinicians make informed choices. People with severe FQ-related problems may reasonably decide to reduce or eliminate the share of industrial meat, intensively farmed fish, and non-tested honey in their diet, especially when alternatives are available.

2. Support for better monitoring. The analytical methods already exist; what is often missing is routine, transparent surveillance with public reporting. Testing programs for infant formula, baby foods, meat, eggs, honey, and water should systematically include fluoroquinolones, not sporadically, and should publish their detection limits and results.

3. Recognition of vulnerable groups. Regulatory toxicology tends to focus on the “healthy adult” and, at most, on children and pregnant women. People with mitochondrial diseases, prior fluoroquinolone toxicity, or other conditions affecting DNA repair and detoxification are usually not considered. As evidence accumulates, it may be necessary to redefine what “safe” means for these populations.

✅......... Finally, this topic should not be used to create panic or helplessness, but to motivate better science and more honest regulation. The fact that fluoroquinolones can be traced from veterinary use to milk, meat, baby foods, honey, water, soil, and vegetables is not a conspiracy theory; it is a documented reality of modern agriculture and pharmacology. The open question – crucial for millions of patients – is how these chronic micro-exposures interact with existing mitochondrial and DNA damage, and whether reducing them can improve long-term outcomes. Until we have clear answers, prudence, transparency, and independent research are the most reasonable path forward - choose your food carefully.

🟦🟦🟦🟦🟦🟦🟦🟦🟦🟦🟦

💊Medications in the fluoroquinolone class (incl: Cipro/ciprofloxacin, Levaquin (off market)/levofloxacin, Avelox/moxifloxacin etc) in all forms for humans and pets: https://fq100.org/drug-list

Find support and resources on our sites:
🌐 Find Us: https://fq100.org/
▶️ YouTube: https://www.youtube.com/
🔵 Facebook: https://www.facebook.com/fqtoxicitystudy/
🐦 X/Twitter: https://twitter.com/FQ_100

⚠️Disclaimer
This text is intended for information and education only. It does not replace individual medical advice, diagnosis or treatment. Decisions about diet, treatment and monitoring of fluoroquinolone-associated problems should always be taken into consultation with qualified healthcare professionals who know the patient’s full clinical situation.

References:
1. Rodríguez E, Moreno-Bondi MC, Marazuela MD. Development and validation of a solid-phase extraction method coupled to liquid chromatography with fluorescence detection for the determination of fluoroquinolone residues in powdered infant formulae. J Chromatogr A. 2008;1209(1–2):136–144.
2. Rodríguez E, Moreno-Bondi MC, Marazuela MD. Multiresidue determination of fluoroquinolone antimicrobials in baby foods by liquid chromatography. Food Chem. 2011;127(3):1354–1360.
3. Rodríguez E, Navarro-Villoslada F, Moreno-Bondi MC, Marazuela MD. Optimization of a pressurized liquid extraction method by experimental design methodologies for the determination of fluoroquinolone residues in infant foods by liquid chromatography. J Chromatogr A. 2010;1217(5):605–613.
4. Herrera-Herrera AV, Hernández-Borges J, Rodríguez-Delgado MA, Cifuentes A. Determination of quinolone residues in infant and young children powdered milk combining solid-phase extraction and UPLC–MS/MS. J Chromatogr A. 2011;1218(42):8423–8431.
5. Foo WY, Loh SH, Wan Mohd Afiq WMK, Ariffin MM. Fluoroquinolone residues in food: occurrence and analytical methods – a mini review from 2000 to 2022. Malays J A**l Sci. 2023;27(3):533–551.
6. Khalifa HO, Shikoray L, Mohamed M-YI, Habib I, Matsumoto T. Veterinary drug residues in the food chain as an emerging public health threat: sources, analytical methods, health impacts, and preventive measures. Foods. 2024;13(11):1629.
7. Gentili A, Perret D, Marchese S, Curini R. Accelerated solvent extraction and confirmatory analysis of sulfonamide residues in raw meat and infant foods by LC–MS/MS. J Agric Food Chem. 2004;52(1):154–160.
8. Herranz S, Moreno-Bondi MC, Marazuela MD. Development of a new sample pretreatment procedure based on pressurized liquid extraction for the determination of fluoroquinolone residues in table eggs. J Chromatogr A. 2007;1140(1–2):63–70.
9. Lolo M, Pedreira S, Miranda JM, et al. Effect of cooking on enrofloxacin residues in chicken tissue. Food Addit Contam. 2006;23(10):988–993.
10. Javadi A, Mirzaie H, Khatibi SA. Effect of roasting, boiling and microwaving cooking methods on enrofloxacin residues in edible tissues of broiler. Afr J Pharm Pharmacol. 2011;5(2):214–218.
11. Kamouh HM, Abdallah R, Kirrella GA, Mostafa NY, Shafik S. Assessment of antibiotic residues in chicken meat. Open Vet J. 2024;14(1):438–448.
12. Kanda M, Kusano T, Kanai S, et al. Rapid determination of fluoroquinolone residues in honey by a microbiological screening method and liquid chromatography. J AOAC Int. 2010;93(4):1331–1339.
13. He L, Shen L, Zhang J, Li R. Comprehensive investigation of fluoroquinolone residues in Apis mellifera and Apis cerana honey and potential risks to consumers: a five-year study (2014–2018) in Zhejiang Province, China. Toxics. 2023;11(9):744.
14. Shoaei M, Foroughi M, Badrzadeh M, et al. Antibiotics in honey: a systematic review and meta-analysis. Int J Environ Health Res. 2024;34(2):1064–1075.
15. Akhter S, Bhat MA, Hashem A, et al. Profiling of antibiotic residues in soil and vegetables irrigated using pharmaceutical-contaminated water in the Delhi stretch of the Yamuna River, India. Water. 2023;15(23):4197.
16. Li X, Xie Y, Wang J, et al. Influence of planting patterns on fluoroquinolone residues in the soil of an intensive vegetable cultivation area in northern China. Sci Total Environ. 2013;458–460:63–69.
17. Rodríguez E, Navarro-Villoslada F, Benito-Peña E, Marazuela MD, Moreno-Bondi MC. Multiresidue determination of ultratrace levels of fluoroquinolone antimicrobials in drinking and aquaculture water samples by automated online molecularly imprinted solid-phase extraction and liquid chromatography. A**l Chem. 2011;83(6):2046–2055.
18. Gothwal R, Shashidhar T. Occurrence of high levels of fluoroquinolones in aquatic environment due to effluent discharges from bulk drug manufacturers. J Hazard Toxic Radioact Waste. 2017;21(3):04016013.
19. Ghimpeţeanu OM, Pogurschi EN, Popa DC, Dragomir N, Dragotoiu T, Mihai OD, Petcu CD. Antibiotic use in livestock and residues in food – a public health threat: a review. Antibiotics. 2022;11(5):676.

Address

845 S. Main Street, Ste. 102
Lombard, IL
60148

Alerts

Be the first to know and let us send you an email when Fluoroquinolone Toxicity Study posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Fluoroquinolone Toxicity Study:

Shortcuts

Share